| Literature DB >> 31312010 |
Satoshi Ohira1,2, Noriko Motoki3, Takumi Shibazaki4, Yuka Misawa5, Yuji Inaba1,6, Makoto Kanai1, Hiroshi Kurita1, Tanri Shiozawa2, Yozo Nakazawa4, Teruomi Tsukahara1,5, Tetsuo Nomiyama1,5.
Abstract
There have been no large nationwide birth cohort studies examining for the effects of maternal alcohol use during pregnancy on placental abnormality. This study searched for associations between alcohol consumption and the placental abnormalities of placenta previa, placental abruption, and placenta accreta using the fixed dataset of a large national birth cohort study commencing in 2011 that included 80,020 mothers with a singleton pregnancy. The presence of placental abnormalities and potential confounding factors were recorded, and multiple logistic regression analysis was employed to search for correlations between maternal alcohol consumption during pregnancy and placental abnormalities. The overall rate of prenatal drinking until the second/third trimester was 2.7% (2,112). The prevalence of placenta previa, placental abruption, and placenta accreta was 0.58% (467), 0.43% (342), and 0.20% (160), respectively. After controlling for potential confounding factors, maternal alcohol use during pregnancy was significantly associated with the development of placenta accreta (OR 3.10, 95%CI 1.69-5.44). In conclusion, this large nationwide survey revealed an association between maternal drinking during pregnancy and placenta accreta, which may lead to excessive bleeding during delivery.Entities:
Mesh:
Year: 2019 PMID: 31312010 PMCID: PMC6635355 DOI: 10.1038/s41598-019-46760-1
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Characteristics of participants with or without placental abnormality.
| Variable | No placental abnormality (controls) | Placenta previa | Placental abruption | Placenta accreta |
|
|---|---|---|---|---|---|
| Participants, n | 79,051 | 467 | 342 | 160 | |
| Maternal age at delivery, years (mean ± SD) | 31.2 ± 5.1 | 33.5 ± 4.7 b | 32.0 ± 5.2 b c | 32.3 ± 5.2b | <0.001a |
| Maternal age group, n (%) | |||||
| <20 years | 674 (0.9) | 0 (0.0) | 5 (1.5) | 0 (0.0) | |
| 20–34 years | 56,798 (71.8) | 250 (53.5) | 216 (63.2) | 96 (60.0) | |
| 35 + years | 21,579 (27.3) | 217 (46.5) | 121 (35.4) | 64 (40.0) | <0.001 |
| Maternal BMI before pregnancy, kg/m2 (mean ± SD) | 21.2 ± 3.3 | 21.3 ± 3.2 | 21.6 ± 3.7 | 21.6 ± 3.4 | 0.10a |
| Maternal BMI group | |||||
| Underweight (BMI < 18.5), n (%) | 12,781 (16.2) | 66 (14.1) | 57 (16.7) | 25 (15.6) | |
| Normal weight BMI 18.5–24.9), n (%) | 57,911 (73.3) | 350 (74.9) | 239 (69.9) | 115 (71.9) | |
| Overweight (BMI 25.0+), n (%) | 8,359 (10.6) | 51 (10.9) | 46 (13.5) | 20 (12.5) | 0.51 |
| Parity | |||||
| Multiparous, n (%) | 45,402 (57.4) | 276 (59.1) | 193 (56.4) | 96 (60.0) | 0.78 |
| Past history of cesarean section, n (%) | 6,968 (8.8) | 56 (12.0) | 47 (13.7) | 8 (5.0) | <0.001 |
| Recurrent pregnancy loss, n (%) | 813 (1.0) | 11 (2.4) | 3 (0.9) | 2 (1.3) | 0.043 |
| Means of pregnancy for current birth, n (%) | |||||
| Spontaneous | 73,967 (93.6) | 394 (84.4) | 310 (90.6) | 123 (76.9) | |
| Ovulation induction through medication | 2,112 (2.7) | 17 (3.6) | 7 (2.0) | 3 (1.9) | |
| Artificial insemination or | 2,972 (3.8) | 56 (12.0) | 25 (7.3) | 34 (21.3) | <0.001 |
| Smoking during pregnancy, n (%) | 3,572 (4.5) | 17 (3.6) | 26 (7.6) | 14 (8.8) | 0.002 |
| Drinking during pregnancy, n (%) | 2,012 (2.5) | 10 (2.1) | 8 (2.3) | 13 (8.1) | <0.001 |
| Maternal drinking frequency, n (%) | |||||
| Infrequent (<3 days per week) | 1438 (1.8) | 6 (1.3) | 4 (1.2) | 9 (8.3) | |
| Frequent (3+ days per week) | 574 (0.3) | 4 (0.9) | 4 (1.2) | 4 (2.5) | 0.001 |
| Maternal drinking amount, n (%) | |||||
| Low (<1.5 drinks per week) | 1508 (1.9) | 6 (1.3) | 4 (1.2) | 10 (6.3) | |
| High (1.5+ drinks per week) | 504 (0.6) | 4 (0.9) | 4 (1.2) | 3 (1.9) | 0.001 |
aDifferences in maternal age and BMI were assessed with one-way repeated measures of ANOVA followed by post-hoc (Bonferroni) testing.
bP-value < 0.001 vs. group of no placental abnormality.
cP-value < 0.001 vs. group of placental previa.
Multivariate logistic regression analysis for placental abnormalities versus controls.
| Variable | Placenta previa (n = 467) | Placental abruption (n = 342) | Placenta accreta (n = 160) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| cOR (95%CI) |
| aOR (95%CI) |
| cOR (95%CI) |
| aOR (95%CI) |
| cOR (95%CI) |
| aOR (95%CI) |
| |
|
| 0.84 (0.45–1.57) | 0.58 | 0.85 (0.45–1.61) | 0.63 | 0.81 (0.45–1.85) | 0.81 | 0.85 (0.42–1.73) | 0.65 | 3.39 (1.92–5.98) | <0.001 | 3.03 (1.69–5.44) | <0.001 |
|
| ||||||||||||
| Non-drinkers (reference) | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | ||||||
| Infrequent (<3 days per week) | 0.70 (0.31–1.58) | 0.39 | 0.72 (0.32–1.61) | 0.42 | 0.64 (0.24–1.72) | 0.38 | 0.63 (0.23–1.69) | 0.36 | 3.28 (1.67–6.44) | 0.001 | 3.02 (1.52–5.99) | 0.002 |
| Frequent (3+ days per week) | 1.18 (0.44–3.15) | 0.75 | 1.20 (0.44–3.25) | 0.72 | 1.61 (0.59–4.32) | 0.35 | 1.33 (0.49–3.62) | 0.58 | 3.65 (1.35–9.89) | 0.011 | 3.06 (1.11–8.48) | 0.031 |
| 0.78 | 0.84 | 0.84 | 0.94 | <0.001 | <0.001 | |||||||
|
| ||||||||||||
| Non-drinkers (reference) | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | ||||||
| Low (<1.5 drinks per week) | 0.67 (0.30–1.50) | 0.33 | 0.68 (0.30–1.53) | 0.35 | 0.61 (0.23–1.64) | 0.33 | 0.59 (0.22–1.60) | 0.30 | 3.48 (1.83–6.61) | <0.001 | 3.18 (1.65–6.11) | 0.001 |
| High (1.5+ drinks per week) | 1.34 (0.50–3.59) | 0.56 | 1.39 (0.51–3.76) | 0.52 | 1.83 (0.68–4.93) | 0.23 | 1.52 (0.56–4.14) | 0.42 | 3.12 (0.99–9.82) | 0.052 | 2.61 (0.81–8.40) | 0.11 |
| 0.85 | 0.91 | 0.77 | 0.99 | <0.001 | 0.001 | |||||||
Multiple logistic regression model was adjusted for maternal age, BMI before pregnancy, menstrual abnormality, recurrent pregnancy loss, parity, history of delivery (including cesarean section and artificial abortion), means of pregnancy, smoking habit, complications during pregnancy (including antiphospholipid antibody syndrome, maternal infection, diabetes mellitus/gestational diabetes mellitus, and hypertensive disorder of pregnancy), and medications during pregnancy (including antibiotics, iron supplements, folic acid supplements, and therapy for recurrent pregnancy loss).
Figure 1Case selection flowchart.